Pfizer (PFE): financials, SEC filings and peers
Pfizer (PFE) is a pharmaceuticals company in the Health Care sector of the S&P 500, headquartered in New York City, New York.
It was founded in 1849 and joined the S&P 500 on March 4, 1957.
Its fiscal year ends in December, and its shares trade on the NYSE.
In its SEC filings it is classified as “Pharmaceutical Preparations”.
Pfizer at a glance
- Revenue (12 months)
- $63.6B
- Revenue growth
- +1.3%
- Operating margin
- 11.0%
- Net income (12 months)
- $4.0B
- Free cash flow (12 months)
- $11.8B
- Cash
- $1.8B
- Debt
- $62.6B
- Diluted EPS (12 months)
- $0.70
Twelve months to September 27, 2026, from the 10-Q filed November 3, 2026.
Latest twelve months
Over the twelve months to September 27, 2026, Pfizer reported revenue of $63.6 billion, about the same as a year earlier (+1.3%).
Its operating margin was 11.0%, down 7.9 percentage points from a year earlier: for every $100 of sales, about $11 was left as operating profit.
Net income was $4.0 billion (6.3% of revenue), 59.0% lower than a year earlier.
Operating cash flow was $14.2 billion and capital spending $2.4 billion, leaving free cash flow of $11.8 billion (18.5% of revenue).
At the end of the period it held $1.8 billion in cash and $62.6 billion in debt, a net debt position of $60.8 billion.
Five-year trend
- Revenue went from $41.7 billion in fiscal 2020 to $62.6 billion in fiscal 2025, about 8.5% a year.
- Free cash flow was positive in each of the last 6 fiscal years.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $81.3B | $101.2B | $59.6B | $63.6B | $62.6B |
| Revenue growth | 95.2% | 24.5% | -41.1% | 6.8% | -1.6% |
| Operating margin | — | — | — | — | — |
| Net income | $22.0B | $31.4B | $2.1B | $8.0B | $7.8B |
| Free cash flow | $29.9B | $26.0B | $4.8B | $9.8B | $9.1B |
| Diluted EPS | $3.85 | $5.47 | $0.37 | $1.41 | $1.36 |
Fiscal years as reported in Pfizer’s 10-K filings. Free cash flow is operating cash flow minus capital spending.
Recent SEC filings
- 8-K filed November 3, 2026 — Executive or director change
- 10-Q filed November 3, 2026 — quarterly report
- 8-K filed November 3, 2026 — Earnings results
- 10-Q filed August 4, 2026 — quarterly report
- 8-K filed August 4, 2026 — Earnings results
- 8-K filed June 18, 2026 — Regulation FD disclosure
- 8-K filed June 18, 2026 — Executive or director change
- 10-Q filed May 5, 2026 — quarterly report
Companies like Pfizer
Other S&P 500 companies in Pharmaceuticals:
- BMYBristol Myers SquibbNew York City, New York
- JNJJohnson & JohnsonNew Brunswick, New Jersey
- LLYLilly (Eli)Indianapolis, Indiana
- MRKMerck & Co.Kenilworth, New Jersey
- VTRSViatrisPittsburgh, Pennsylvania
- ZTSZoetisParsippany, New Jersey
More from Health Care
Questions about Pfizer
Is Pfizer's revenue growing?
Yes. Revenue for the twelve months to September 27, 2026 was $63.6 billion, up 1.3% from a year earlier, according to its SEC filings.
Is Pfizer profitable?
Yes. It earned $4.0 billion in net income over the twelve months to September 27, 2026, a net margin of 6.3%.
Does Pfizer have more cash or more debt?
At September 27, 2026 it had $1.8 billion in cash and $62.6 billion in debt, so more debt than cash.
When did Pfizer last file financial results?
Its latest quarterly report (10-Q) was filed with the SEC on November 3, 2026.
Which companies are similar to Pfizer?
In the S&P 500, Pfizer is grouped in Pharmaceuticals within the Health Care sector. Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ), Lilly (Eli) (LLY), Merck & Co. (MRK), Viatris (VTRS) are in the same group.
Understand the numbers
Source: Pfizer’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved November 11, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.